Moderna raises full-year COVID vaccine sales forecast to $21 billion

(Reuters) – Moderna Inc (MRNA.O) on Thursday raised its full-year forecast for sales of its COVID-19 vaccine to roughly $21 billion from $19 billion.

The company in February forecast sales of $19 billion from its signed contracts, and option for $3 billion in additional purchases.

A vial and sryinge are seen in front of a displayed Moderna logo in this illustration taken January 11, 2021. REUTERS/Dado Ruvic/Illustration

Moderna on Thursday forecast additional purchases of roughly $500 million.

Reporting by Manas Mishra in Bengaluru

Our Standards: The Thomson Reuters Trust Principles.


Reuters source: